Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.145

From GxPlex

Revision as of 17:29, 15 July 2026 by imported>GxPlexBot (Import from GxPlex Excel)
Jump to: navigation, search



Document information
Reference USA 21 CFR Part 812 09-Apr-2025
Validity area USA
Scope(s) MD
Document name 21 CFR Part 812
Version / Revision 09-Apr-2025
Status Current
Document type Legal act
Language(s) EN
Description Title 21 —Food and Drugs

Chapter I —Food and Drug Administration, Department of Health and Human Services Subchapter H—Medical Devices Part 812 Investigational Device Exemptions https://www.ecfr.gov/current/title-21

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Module Module 4 — Unit 4.5.2
Scope MD
Document part § 812.145
Language EN
Original entry by Florian Adragna
Contributors
Tags Inspection, FDA, Sponsor, Medical device, Investigator
Comment Sponsor and investigator inspection obligations (device IDE)

Content

§ 812.145 Inspections (a) Entry and inspection. A sponsor or an investigator who has authority to grant access shall permit authorized FDA employees, at reasonable times and in a reasonable manner, to enter and inspect any establishment where devices are held (including any establishment where devices are manufactured, processed, packed, installed, used, or implanted or where records of results from use of devices are kept).

(b) Records inspection. A sponsor, IRB, or investigator, or any other person acting on behalf of such a person with respect to an investigation, shall permit authorized FDA employees, at reasonable times and in a reasonable manner, to inspect and copy all records relating to an investigation.

(c) Records identifying subjects. An investigator shall permit authorized FDA employees to inspect and copy records that identify subjects, upon notice that FDA has reason to suspect that adequate informed consent was not obtained, or that reports required to be submitted by the investigator to the sponsor or IRB have not been submitted or are incomplete, inaccurate, false, or misleading.